Importantly, the cancer cells used in this study were from an HCL-v patient (Patient 058), and generally, these patients do not respond well to frontline therapies, suggesting that BAFF neutralization could potentially sensitize these patients to frontline chemotherapy. Here, TNFSF13B is linked to cancer.